

PATENT
Attorney Docket No. 223316
Client Reference No.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kasid et al.

Group Art Unit: 1635

Application No. 10/627,571

Examiner: Jon Ashen

Filed: July 25, 2003

For: ANTI-APOPTOTIC GENE SCC-S2 AND

DIAGNOSTIC AND THERAPEUTIC

**USES THEREOF** 

#### INFORMATION DISCLOSURE STATEMENT

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Kasid et al. Application No. 10/627,571

	of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).  NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copie	s of the References
	Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
	Copies of U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. Copies of other references identified on the accompanying Form 1449 are enclosed herewith with the exception of Chin (March, 2002). A paper copy of the first 2 pages of the Chin reference is provided. The complete reference, which is approximately 10,000 pages, is provided on the enclosed CD-ROM, which is the format in which it was initially transmitted to us by a third party.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
	A copy of the foreign search report is enclosed herewith.

			·		
	parent application furnished at that submitted herewith The Examiner is accordance with Procedure. In according the procedure of the procedure	ted on the enclosed Form (s) of the present application. Accordingly, add a, so as not to burden the respectfully requested the requirements set of ordance with 37 CFR 1.98 an earlier filing date under eviously furnished are set	ation, and coplitional copies e file with dup to carefully ut in the Ma (d), the details der 35 USC 1	pies of the reference of the reference copie review the nual of Pats of the parer	references were erences are not s of references. references in ent Examining at application(s)
	U.S. APPLI	CATIONS	St	atus (check o	ne)
	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1.					
2.					,
3.					
Stater	nent under 37 CFR	1.97(e)			
	Information Discleriforeign patent office	hereby states that each osure Statement was fince in a counterpart foreing of the Information	rst cited in a gn patent appl	ny commun ication not r	ication from a
	Information Disclo office in a counte undersigned after r Information Discl	hereby states that no sure Statement was cited erpart foreign patent apmaking reasonable inquir osure Statement was known than three months ent.	in a community plication, and y, no item of it	cation from a to the known to t	a foreign patent owledge of the contained in the designated in
Stater	nent under 37 CFR	1.704(d)		•	
	Information Disclo office in a counter any individual desi	hereby states that each sure Statement was cited part application and that ignated in 37 CFR 1.56(d) Disclosure Statement.	in a communi this commun	cation from a	a foreign patent not received by
Fees					
$\boxtimes$	No fee is owed by The IDS Fee of \$1	the applicant(s). 80 under 37 CFR 1.17(p)	is enclosed he	erewith.	

In re Appln. of Kasid et al. Application No. 10/627,571



## Method of Payment of Fees

Attached is a check in the amount of \$	
Charge Deposit Account No. 12-1216 in the amount of \$	. (A duplicate copy of
this communication is enclosed for that purpose.)	

### **Authorization to Charge Additional Fees**

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

# Instructions as to Overpayment,

Credit Account No. 12-1216.
Refund

M. Daniel Hefner, Reg. No. 41,826 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: May 25, 2005

#### **CERTIFICATE OF MAILING**

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: // 24 26

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of
------------

	Complete if Known	
Application Number	10/627,571	
Filing Date	July 25, 2003	
First Named Inventor	Kasid et al.	
Group Art Unit	1635	
Examiner Name	Ashen, Jon Benjamin	
Attorney Docket Number	223316	

				U.S. PATENT DOCUMENTS		
	_	U.S. Patent Do	cument	·		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	СС	RE 30,985		Cartaya	June 29, 1982	
	CE	4,399,216		Axel et al.	Aug. 16, 1983	
	CF	4,551,433		DeBoer	Nov. 5, 1985	
	CG	4,560,655		Baker	Dec. 24, 1985	<del>,,</del>
	СН	4,657,866	1	Kumar	Apr. 14, 1987	_
	CI	4,767,704		Cleveland et al.	Aug. 30, 1988	
-	CJ	4,745,051		Smith et al.	May 17, 1988	
	СК	4,777,127		Suni et al.	Oct. 11, 1988	
	CL	4,816,567		Cabilly et al.	Mar. 28, 1989	······
	СМ	4,837,148		Cregg	June 6, 1989	
	CN	4,889,806		Olson et al.	Dec. 26, 1989	
	СО	4,927,762		Darfler	May 22, 1990	
	CP	4,929,555		Cregg et al.	May 29, 1990	• • •
•	CQ	4,959,314		Mark et al.	Sep. 25, 1990	
	CR	5,013,830		Ohtsuka et al.	May 7, 1991	····
	CS	5,091,309	Α	Schlesinger et al.	Feb. 25, 1992	
	CT	5,149,655	Α	McCabe et al.	Sep. 22, 1992	
	CU	5,149,797	Α	Pederson et al.	Sep. 22, 1992	
	CV	5,185,440	Α	Davis et al.	Feb. 9, 1993	
	CW	5,206,152	Α	Sukhatme	Apr. 27, 1993	
	CX	5,217,879	Α	Huang et al.	Jun. 8, 1993	
	CY	5,219,740	Α	Miller et al.	Jun. 15, 1993	
	CZ	5,403,711	Α	Walder et al.	Apr. 4, 1995	· · · · · · ·
	DA	5,422,120	Α	Kim	Jun. 6, 1995	
	DB	5,491,133	Α	Walder et al.	Feb. 13, 1996	
	DC	5,514,758	Α	Muller et al.	May 7, 1996	-
	DD	5,530,101	Α	Queen et al.	Jun. 25, 1996	
	DE	5,536,821	Α	Agrawal et al.	July 16, 1996	
	DF	5,541,306	Α	Agrawal et al.	July 30, 1996	
	DG	5,550,111	Α	Suhadolnik et al.	Aug. 27, 1996	
	DH	5,563,253	Α	Agrawal et al.	Oct. 8, 1996	
	ÐΙ	5,565,552	Α	Magda et al.	Oct. 15, 1996	
	DJ	5,565,350	Α	Kmiec	Oct. 15, 1996	
	DK	5,567,810	Α	Weis et al.	Oct. 22, 1996	
	DL	5,571,799	Α	Tkachuk et al.	Nov. 5, 1996	
	DM	5,574,142	Α	Meyer, Jr. et al.	Nov. 12, 1996	
	DN	5,580,859	Α	Felgner et al.	Dec. 3, 1996	
	DO	5,585,481	Α	Arnold, Jr. et al.	Dec. 17, 1996	
	DΡ	5,585,089	Α	Queen et al.	Dec. 17, 1996	
	DQ	5,587,371	Α	Sessler et al.	Dec. 24, 1996	
	DR	5,587,361	Α	Cook et al.	Dec. 24, 1996	7-71
	DS	5,597,696	Α	Linn et al.	Jan. 28, 1997	<del></del> .
	DT	5,610,018	Α	Di Fiore et al.	Mar. 11, 1997	
	DU	5,625,050	Α	Beaton et al.	Apr. 29, 1997	
	DV	5,641,670	Α	Treco et al.	Jun. 24, 1997	

	DW	5,652,355	Α	Metelev et al.	July 29, 1997	
	DΧ	5,700,922	Α	Cook	Dec. 23, 1997	
	DY	5,776,745	A.	Ketner et al.	Jul. 7, 1998	
	DΖ	5,801,154	Α	Baracchini et al.	Sept. 1, 1998	
	EΑ	5,919,773	Α	Monia et al.	Jul. 6, 1999	
	ΕB	5,939,598	Α	Kucherlapati et al.	Aug. 17, 1999	
	EC	5,958,773	Α	Monia et al.	Sep. 28, 1999	
	ED	6,333,314	B1	Kasid et al.	Dec. 25, 2001	
	EF	60/264,062		Kumar et al.		Jan. 26, 2001
	EG	60/281,780		Kasid et al.		Apr. 6, 2001
	ΕH	60/382,031		Gokhale et al.		May 22, 2002
	ΕI	60/371,126		Kasid et al.		Apr. 10, 2002
	ΕJ	60/281,779		Kasid et al.		Apr. 6, 2001
	EK	60/281,785		Kasid et al.		Apr. 6, 2001
	EL	60/371,116		Kasid et al.		Apr. 10, 2002
	ΕM	60/281,796		Kasid et al.		Apr. 6, 2001
	ΕN	10/056,210		Kasid et al.		Jan. 28, 2002
	ΕO	10/411,931		Kasid et al.	Dec. 4, 2003	Apr. 10, 2003
	ΕP	10/411,930		Kasid et al.	Jan. 8, 2004	Apr. 10, 2003
	EQ	10/443,273		Gokhale et al.	Dec. 11, 2003	May 22, 2003
<u>-</u>	ER	10/627,571		Kasid et al.	Apr. 29, 2004	Jan. 28, 2002
	ES	10/679,561		Kasid et al.	Jun. 3, 2004	Oct. 6, 2003
	ET	10/679,865		Kasid et al.	Jun. 17, 2004	Oct. 6, 2003
-	ΕU	10/680,313		Kasid et al.	Aug. 19, 2004	Oct. 6, 2003
	ΕV	10/679,580		Kasid et al.	Dec. 9, 2004	Oct. 6, 2003

	_			FORE	IGN PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
	l _	F	oreign Patent Document				Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	EW	wo	87/00195	A1	Celltech Limited	Jan. 15, 1987		
	EX	wo	90/03430	A1	Cetus Corporation	Apr. 5, 1990		
	EY	wo	90/07936	A1	Chiron Corporation	Jul. 26, 1990		1
	ΕZ	WO	90/11092	A1	Vical, Inc.	Oct. 4, 1990		
	FA	WO	91/00357	_ A1	Cayla	Jan. 10, 1991		X <sup>+</sup>
	FB	WO	91/02805	A2	Viagene, Inc.	Mar. 7, 1991		
,	FC	wo	91/10741	A1	Cell Genesys, Inc.	Jul. 25, 1991		
	FD	WO	91/14445	A1	Research Development Foundation	Oct. 3, 1991		-
	FE	WO	92/05266	A2	Viagene, Inc.	Apr. 2, 1992		
	FF	WO	92/10578	A1	Bioption AB	Jun. 25, 1992		
	FG	wo	92/11033	A1	Arch Development Corporation	Jul. 9, 1992		
	FH	WO	93/03769	A1	The United States of America, Department of Health and Human Services	Mar. 4, 1993		
	FI	wo	93/04170	A1	The United States of America, Department of Health and Human Services	Mar. 4, 1993		
	FJ	wo	93/06248	A1	The United States of America, Department of Health and Human Services	Apr. 1, 1993		
	FK	wo	93/09239	A1	Research Corporation Technologies	May 13, 1993		
	FL	WO	93/10218	A1	The United States of America, Department of Health and Human Services	May 27, 1993		
	FΜ	WO	93/11230	A1	Dynal AS	Jun. 10, 1993		
	FN	WO	93/19191	A1	Centre National De LA Recherche Scientifique	Sep. 30, 1993		X⁺
	FO	WO	93/25234	A1	The Regents of the University of California	Dec. 23, 1993		

	FP	WO	93/25698	A1 .	The United States of America, Department of Health and Human Services	Dec. 23, 1993	
	FQ	WO	94/02602	A1	Cell Genesys, Inc.	Feb. 3, 1994	
	FR	WO	94/03622	A1	Imperial College of ?Science, Technology & Medicine	Feb. 17, 1994	
	FS	WO	94/12649	A2	Genzyme Corporation	Jun. 9, 1994	
	FT	wo	94/15645	A1	Texas Biotechnology Corporation	Jul. 21, 1994	
	FU	wo	94/21792	A2	Viagene, Inc.	Sep. 29, 1994	
	FV	wo	94/23697	A1	Depotech Corporation	Oct. 27, 1994	
	FW	wo	94/28938	A1	The Regents of the University of Michigan	Dec. 22, 1994	
	FX	WO	95/00655	A1	Mc Master University	Jan. 5, 1995	
	FY	WO	95/07994	A2	Viagene, Inc.	Mar. 23, 1995	
	FZ	wo	95/11984	A2	Canji, Inc.	May 4, 1995	
	GA	wo	95/13796	A1	Depotech Corporation	May 26, 1995	
	GB	wo	95/27044	A1	Bioption AB	Oct. 12, 1995	
	GC	wo	95/27069	A1	Smithkline Beecham Biologicals	Oct. 12, 1995	
	GD	wo	95/30763	A2	Viagene, Inc.	Nov. 16, 1995	
	GE	wo	96/30498	A1	Xenotech Incorporated	Oct. 3, 1996	
·	GF	wo	96/33735	A1	Cell Genesys, Inc.	Oct. 31, 1996	
	GG	wo	96/34096	A1	Cell Genesys, Inc.	Oct. 31, 1996	
	GH	wo	98/24893	A2	Abgenix, Inc.	Jun. 11, 1998	
·	GI	wo	00/00157	A2	Georgetown University Medical Center	Jan. 6, 2000	
	G1	WO	02/059337	A1	Georgetown University School of Medicine	Aug. 1, 2002	
	GK	wo	02/081639	A2	Georgetown University	Oct. 17, 2002	
	GL	wo	02/081640	A2	Georgetown University	Oct. 17, 2002	
	GM	wo	02/081641	A2	Georgetown University	Oct. 17, 2002	
	GN	WO	02/081642	A2	Georgetown University	Oct. 17, 2002	
	GO	EP	36,776	A2	Genentech, Inc.	Sep. 30, 1981	
	GP	EP	0 127 839	A2	The Texas A&M University System	Dec. 12, 1984	
	GQ	EP	0 155 476	A1	Idaho Research Foundation	Sep. 25, 1985	
	GR	EP	0 244 234	A2	Alko Ltd.	Nov. 4, 1987	
	GS	EP	0 345 242	A2	Smithkline Biologicals S.A.	Dec. 6, 1989	X <sup>+</sup>
	GT	EP	0 415 731	A2	The Wellcome Foundation Limited	Mar. 6, 1991	
	Gυ	EP	0 524 968	B1	Depotech Corporation	Feb. 3, 1993	
	GV	EP	1074617	A2	Helix Research Institute	Feb. 7, 2001	
	GW	GB	2 200 651	Α	Ayad Mohamed Khalaf Al- Sumidale	Aug. 10, 1988	

		OTHER - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher,	Trans Yes	No*+
<u> </u>	GX	city and/or country where published.  ALTSCHUL et al., Nucleic Acids Research, 25(17), 3389-3402 (1997)		
	GY	ALVAREZ et al., The Journal of Biological Chemistry, 266(23), 15277-15285 (1991)		
	GZ	BARBA et al., Journal of Neurosurgery, 79(5), 729-735 (1993)		
	HA	BACCARINI et al., The Journal of Biological Chemistry, 266(17), 10941-10945 (1991)		
	НВ	BAIN et al., Gene Therapy, 1(S68), (1994)		
	нс	BALLANCE et al., Biochemical and Biophysical Research Communications, 112(1), 284-289 (1983)		
	HD	BARNES et al., Analytical Biochemistry, 102(2), 255 (1980)		
	HE	Basic and Clinical Immunology, 217-262 (Sites and Terr eds., Appleton & Lange, Norwalk, CT 1991)		
	HF	BEACH et al., Nature, 300(5894), 706-709 (1981)		
	HG	BELYAVSKY et al., Nucleic Acids Research 17(8), 2919-2932 (1989)		
	НН	BERKNER, BioTechniques, 6(7), 616-629 (1988)		I
	HI	BERNS et al., Annals of The New York Academy of Sciences, 772, 95-104 (1995)		
	HJ	BOSHART et al., Cell, 41(2), 521 (1985)		

	ע ע	BOWIE et al., Science, 247(4948), 1306-1310 (1990)	
	HK HL	BRANCH et al., <i>Trends in Biochemical Sciences</i> , 23(266), 45-50 (1998)	
_	НМ	BRUDER et al., Genes & Development, 6(4), 545-556 (1992)	
	HN	BRUHN et al., Proceedings of the National Academy of Sciences of the United States of	
	''''	America, 89, 2307-2311 (1992)	
	но	BURUHAM et al., American Journal of Hospital Pharmacy 51(2), 210-218 (1994)	
	HP	CAILLAUD et al., European Journal of Neuroscience, 5(10), 1287-1291 (1993)	
•	HQ	CAPLEN et al., Proceedings of the National Academy of Sciences of the United States	
		of America, 98(17) 9742-47 (2001)	LL
	HR	CARBONELL et al., <i>Gene, 73(2), 409-418 (1988)</i>	
	HS	CARROLL et al., The Journal of Biological Chemistry, 266(23) 14964-14969 (1991)	
	HT	CARPRINO et al., The Journal of Organic Chemistry, 37, 3404-3409 (1972)	
	ΗU	CHANG et al., <i>Nature, 275(5681),</i> 617-624 (1978)	
	ΗV	CHIN, "On the preparation and utilization of isolated and purified oligonucleotides",	
	1110/	Katherine R. Everett Law Library of the University of North Carolina, March 2002	<del> </del>
	HW	CHOTHIA et al., Journal of Molecular Biology, 196(4) 901-917 (1987)	
	нх	CHUNG et al., Proceedings of the National Academy of Sciences of the United States of America, 88(11), 4981- (1991)	
	НΥ	CLELAND et al., Critical Reviews in Therapeutic Drug Carrier Systems, 10(4), 307-377 (1993)	
	ΗZ	CONNELLY, Human Gene Therapy, 6(2), 185-193 (1995)	
	IA	COZENS et al., Journal of Molecular Biology, 206(2), 261-280 (1989)	
	ΙB	CREGG et al., Molecular and Cellular Biology, 5(12), 3376-3385 (1985)	
	1C	CUNNINGHAM et al., <i>Science, 244(108),</i> 1081-1085 (1989)	
	1 D	CURIEL et al., <i>Human Gene Therapy, 3(2),</i> 147-154 (1992)	
•	ΙE	DAS et al., <i>Journal of Bacteriology, 158(3),</i> 1165-1167 (1984)	
	۱F	DAVIDOW et al., Current Genetics, 10(1), 39-48 (1985)	
	IG	DAVIS, The New Biologist, 2(5), 410-419 (1990)	
	H	DAVIS et al., Enzyme Engineering, 4, 169-73 (1978)	
	=	DAYHOFF et al., Atlas of Protein Sequence and Structure, 5(Supplement 3), 345-352 (1978)	
	IJ	DE BOHR et al., Proceedings of the National Academy of Sciences of the United States of America, 80(1), 21-25 (1983)	
	ΙK	DE LOUVENCOURT et al., Journal of Bacteriology, 154(2), 737-742 (1983)	
	TL	DENT et al., Science, 257(5075), 1404-1407 (1992)	
	IМ	DEVARY et al., Cell, 71, 1081-1091 (1992)	
	IN	DE VOS et al., Science, 255(5042), 306-312 (1992)	
	10	DIJKEMA et al., <i>The EMBO Journal</i> , <i>4</i> (3), 761 (1985)	
	IP	DINCHUK et al., The Journal of Biological Chemistry, 275(50), 39543-39554 (2000)	
	IQ	DOWNING et al., <i>Cell, 85(4),</i> 597-605 (1996)	
	IR	ELBASHIR et al., <i>Nature, 411(6836),</i> 494-98 (2001)	
	IS	FABIAN et al., Molecular and Cellular Biology, 13(11), 7170 (1993)	
	ΙT	FEDEROFF et al., Proceedings of the National Academy of Sciences of the United States of America, 89(5), 1636-40 (1992)	
	ΙU	FELGER et al., Human Gene Therapy, 7(15), 1791-1793 (1996)	
	IV	FIERMONTE et al, The Journal of Biological Chemistry, 276(11), 8225-8230 (2001)	
	ΙW	FINCO et al., The Journal of Biological Chemistry, 268(24), 17676-17679 (1993)	
	ΙX	FINK et al., Annual Review of Neuroscience, 19, 265-87 (1992)	
	ΙΥ	FLOTTE et al., Proceedings of the National Academy of Sciences of the United States	
	ļ	of America, 90(22), 10613-10617 (1993)	
<u></u>	ΙZ	FRIDEN et al., Science, 259, 373-377 (1993)	
	JA	FRIESEN et al., The Molecular Biology of Baculoviruses, 31-49 (1986)	<del>                                     </del>
ļ	JB	GAILLARDIN et al., Current Genetics, 10, 49-58 (1985)	<del>                                     </del>
	1C	GALFRE et al., Methods in Enzymology; Immunochemical Techniques, 73, 3-46 (1981)	<del>                                     </del>
	1D	GARDNER et al., The Journal of Biological Chemistry, 268(24) 1789617901(1993)	<del>                                     </del>
	JE	GILLE et al., <i>Nature</i> , 358(6385), 414-417 (1992)	<del>                                     </del>
<u></u>	JF	GLEESON et al., The Journal of General Microbiology, 132(12), 3459-3465 (1986)	<del>                                     </del>
	JG	GOEDDEL et al., Nature, 281(5732), 544 (1979)	<del>                                     </del>
<u></u>	JH	GOEDDEL et al., Nucleic Acids Research, 8(18), 4057-4074 (1980)	<del>                                     </del>
	JI	GOKHALE et al., Gene Therapy, 4(12), 1289-1299 (1997)	<del>                                     </del>
L	71	GONZALEZ et al., Current Opinion in Biotechnology, 9(6), 624-631 (1998)	

	JK	GORMAN et al., Proceedings of the National Academy of Sciences of the United States	
		of America, 79(22), 6777-6781 (1982)	
	JL	GORUPPI et al., <i>FEBS Letters, 415(1),</i> 59-63 (1997)	
	JM	GREEN et al., <i>Science</i> , 281(5381), 1309-1312 (1998)	
	JN	GUZMAN et al., Circulation Research, 73(6), 1202-1207 (1993)	
	JO	GUZMAN et al., Circulation, 88(6), 2838-2848 (1993)	
	JΡ	HAM et al., Methods in Enzymology, 58, 44-93 (1979)	
	JQ	HEIDECKER et al., Molecular and Cellular Biology, 10(6), 2503-2512 (1990)	
	JR	HEIDECKER et al., Advances in Cancer Research, 58, 53-73 (1992)	
	JS	HIGGINS et al., Computer Applications in the Biosciences, 8(2), 189-191 (1992)	
	JT	HINNEN et al., Proceedings of the National Academy of Sciences, 75(4), 1929-1933	
	] " '	(1978)	
	JU	HOULDWORTH et al., Proceedings of the National Academy of Sciences of the United	
	İ	States of America, 85(1), 377-381 (1988)	
	JV	HOWE et al., Cell, 71(2), 335-342 (1992)	
	JW	ITO et al., Journal of Bacteriology, 153(1), 163-168 (1983)	
	JX	JAFFE et al., Nature Genetics, 1(5), 372-378 (1992)	
	JY	JOLLY, Cancer Gene Therapy, 1(1), 51-64 (1994)	
	JZ	JONES et al., <i>Nature</i> , <i>321</i> ( <i>6069</i> ), <i>522-525</i> (1986)	
	KA	KAPLITT, Nature Genetics, 8(2), 148-154 (1994)	
	KB	KASID et al., <i>Science</i> , 238(4818), 1039-1041 (1987)	
	KC	KASID et al., <i>Advances in Cancer Research</i> , 61, 195-233 (1993)	
<u> </u>	KD	KASID et al., <i>Nature, 382(6594),</i> 813-816 (1996)	
		KASS-BISLER et al., Proceedings of the National Academy of Sciences of the United	
-	KE	States of America, 90(24), 11498-11502 (1993)	
	KF	KELLY et al., <i>The EMBO Journal</i> , <i>4</i> (2), 475-479 (1985)	
		KELSON et al., <i>Biochimica Et Biophysica Acta, 1335(1-2),</i> 99-110 (1997)	
	KG		
	KH	KETTLEBOROUGH et al., Protein Engineering., 4(7), 773-83 (1991)	<del></del>
	KI	KIMURA, <i>Human Gene Therapy</i> , <i>5</i> (7), 845-852 (1994)	
	KJ	KISSIL et al., The EMBO Journal, 18(2), 353-362 (1999)	
	KK	KIZAKA-KONDOH et al., Molecular and Cellular Biology, 12(11), 5078-5086 (1992)	
	KL	KOIDE et al., Proceedings of the National Academy of Sciences of the United States of	
	1/1	America, 90(18), 8683 (1993)	
	KM	KOLAROV et al., The Journal of Biological Chemistry, 265(21), 12711-12716 (1990)	
	KN	KOLCH et al., Nature, 349(6308), 426-428 (1991)	
	ко	KOLLS et al., Proceedings of the National Academy of Sciences of the United States of	
	1.5	America, 91(1), 9215-219 (1994)	
	KP	KORIOTH et al., Gene, 150(2), 395-399 (1994)	
1	KQ	KRUG et al., Methods in Enzymology; Guide to Molecular Cloning Techniques, 152,	
	1.45	316-325 (1987)	
	KR	KUNZE et al., Journal of Basic Microbiology, 25(2), 141-144 (1985)	
	KS	KURTZ et al., Molecular and Cellular Biology, 6(1), 142 (1986)	
	KT	KYRIAKIS et al., Nature, 358(6385), 417-421 (1992)	
	ΚU	LAWSON et al., The Journal of Biological Chemistry, 263(29), 14812-14818 (1988)	
	ΚV	LEBACQ-VERHEYDEN et al., Molecular and Cellualr Biology, 8(8), 3129 (1988)	
	KW	LEE et al., The Journal of Biological Chemistry, 266(16), 10351-10357 (1991)	
	KX	LEVERO et al., Gene, 101(2), 195-202 (1991)	
	KY	LI et al., <i>Human Gene Therapy, 4(4),</i> 403-409 (1993)	
	KZ	LI et al., Proceedings of the National Academy of Sciences, 90(20), 9247-9251 (1993)	
	LA	LIANG et al., Science, 257(5072), 967-971 (1992)	
	LB	LIM et al., Gene, 255, 35-42 (2000)	
	LC	LUCIAKOVA et al., Biochemical Journal, 352(2), 519-523 (2000)	
	LD	LUCKOW et al., Bio/Technology, 6(1), 47-55 (1988)	
	LE	MACDONALD et al., Molecular and Cellular Biology, 13(11), 6615-6620 (1993)	
	LF	MAEDA et al., <i>Nature</i> , 315(6020), 592-594 (1985)	
<u> </u>	LG	MARSHALL et al., Cell, 80(2), 179-185 (1995)	<del>  </del>
	<del></del>		<del></del>
<b></b>	LH	MARTENS et al., Analytical Biochemistry, 273(1), 20-31 (1999)	<del></del>
<b></b>	LI	MARTIN et al., <i>DNA</i> , 7(2), 99-106 (1988)	<del>  </del>
	LJ	MARZO et al., The Journal of Experimental Medicine, 187(8), 1261-1271 (1998)	<del>  </del>
<b></b>	LK	MENDELSON et al., Virology, 166, 154-165 (1988)	<del>  </del>
	<u>  LL</u>	MERRIFIELD et al., Journal of the American Chemical Society, 85, 2149-2154 (1963)	

	1 3 2	MILLED et al. Constin Engineering 9 277 270 (4006) (Catlany et al. ad.)		
	LM	MILLER et al., Genetic Engineering, 8, 277-279 (1986) (Setlow et al. ed.)	<del></del>	
	LN MILLER, Annual Review of Microbiology, 42, 177-199 (1988)			
	LO	MILSTEIN et al., Nature, 256(5517), 495-497 (1975)		
	LP	MIYAJIMA et al., Gene, 58(2&3), 273-281 (1987)		
	LQ	MONIA et al., Nature Medicine, 2(6), 668-675 (1996)		
	LR	MORRISON et al., The Journal of Biological Chemistry, 268(23), 17309-17316 (1993)		
ė	LS	MORRISON et al., Proceedings of the National Academy of Sciences of the United		
		States of America, 81(21), 6851-6855 (1984)		
	LT	MORRISON et al., Advances in Immunology, 44, 65-92 (1988)		
•	LU	NAKAMURA et al., The Journal of Biological Chemistry, 274(32), 22476-22483 (1999)		
	LV NECKELMANN et al., Proceedings of the National Academy of Sciences of the United			
		States of America, 84(21), 7580-7584 (1987)		
	LW	OHMICHI et al., The Journal of Biological Chemistry, 267(21), 14604-14610 (1992)		
	LX	OSTADE et al., <i>Nature, 361(6409),</i> 266-269 (1993)		
	LY	PADLAN et al., <i>Molecular Immunology</i> , 28(4/5), 489-498 (1991)		
	LZ	PADLAN et al., <i>Molecular Immunology</i> , 31(3), 169-217 (1994)		
	MA	PATEL et al., Molecular Carcinogenesis, 18(1), 1-6 (1997)		
	МВ	PATEL et al., ACTA Oncological, 37(5), 475-478 (1998)		
	мс	PFEIFER et al., Proceedings of the National Academy of Sciences of the United States		
		of America, 86(24),10075-10079 (1989)		
	MD	PFEIFER et al., Biochemical and Biophysical Research Communications, 252(1), 481-		
· .		486 (1998)		
	МE	PHILIP, Molecular and Cellular Biology, 14(4), 2411-2418 (1994)		
	MF	PINCKARD et al., Clinical and Experimental Immunology, 2, 331-340 (1967)		
	MG	PRASAD et al., Molecular and Cellular Biology, 12(11), 5260-5267 (1992)		
•	МН	PULVERER et al., <i>Nature, 353(6345),</i> 670 (1991)		
	МІ	QURESHI et al., The Journal of Biological Chemistry, 266(31), 20594-20597 (1991)		
	МJ	RAM et al., Cancer Research, 53(1), 83-88 (1993)		
	MK	RAPP et al, <i>The Oncogene Handbook,</i> (Elsevier Science Publishers, New York), 213-		
	''''	253 (1988)		
	ML	RAPP, Oncogene, 6(4), 495-500 (1991)		
	ММ	REBAY et al., Cell, 67, 687-699 (1991)		
	MN	REES et al., <i>The EMBO Journal</i> , 7(7), 2053-2061 (1988)		
	МО	RIEDEL et al., European Journal of Immunology, 12, 3146-3150 (1993)		
ļ	MP	ROBBINS et al., <i>Diabetes, 36(7), 838-845</i> (1987)		
<del></del>	MQ	ROGERS et al., <i>Genomics</i> , 39(2), 127-135 (1997)		
	MR	ROGGENKAMP et al., Molecular & General Genetics, 202(2), 302-308 (1986)		
<u></u>				
	MS_	ROSENFELD et al., Science, 252(5004), 431-434 (1991)		
	MT	SAMUELS et al., <i>Molecular and Cellular Biology</i> , <i>13(10)</i> , 6241-6252 (1993)		
	MU	SAMULSKI et al., <i>Journal of Virology, 63(9), 3822-3828 (1989)</i>		
<u> </u>	MV	SARUBBI et al., Analytical Biochemistry, 237(1), 70-75 (1996)		
	M	COLLAND at al. The Journal of Biological Chamistry, 269(07), 20020, 20020, (4002)		
<u></u>	W	SCHAAP et al., The Journal of Biological Chemistry, 268(27), 20232-20236 (1993)	<del></del>	
	MX	SCHNEIDER et al., <i>Tetrahedron Letters</i> , <i>31(3)</i> , 335-338 (1990)		
	MY	SETH et al., The Journal of Biological Chemistry, 266(35), 23521 (1991)		
	MZ	SIEBENLIST et al., Cell, 20(1), 269 (1980)		
	NA	SIEGEL et al., The Journal of Immunology, 151(8), 4116-4127 (1993)		
	NB	SMITH et al., Proceedings of the National Academy of Sciences of the United States of		
	<del> </del>	America, 82(24), 8404-8408 (1985)		
	NC	SMITH et al., Journal of Molecular Biology, 224(4), 899-904 (1992)		
	ND	SMITH et al., Advances in Applied Mathematics, 2(4), 482-489 (1981)	<b></b>	
	NE	SOLDATENKOV et al., The Cancer Journal from Scientific American, 3(1), 13-20 (1997)		
	NF	SOZERI et al., Oncogene, 7(11), 2259 (1992)		
	NG	STANTON et al., Molecular and Cellular Biology, 9(2), 639-647 (1989)		
	NH	STENFLO, Blood, 78(7). 1637-1651 (1991)		
	NI	STOKOE et al., The EMBO Journal, 11(11), 3985-3994 (1992)		
	NJ	STURGILL et al., Nature, 334(6184), 715-718 (1988)		
	NK	SUN et al., Hepatology, 27(1), 228-239 (1998)		
	NL	SUNNERHAGEN et al., The Journal of Biological Chemistry, 268(31), 2339-2344		
	1	(1993)	<u>                                       </u>	
	NM	SUY et al., Oncogene, 15(1), 53-61 (1997)	·	
<del></del>				

			<del></del> -			
	NN	SUY et al., The Journal of Biological Chemistry, 273(28), 1787117878 (1998)	<del></del>			
	NO	TAKAMIYA et al., Journal of Neuroscience Research, 33(3), 493-503 (1992)				
	NP	TILBURN et al., <i>Gene, 26(2&amp;3),</i> 205-221 (1983)				
	NQ	TORNKVIST et al., The Journal of Biological Chemistry, 269(19), 13919-13921 (1994)				
	NR	TRAVERSE et al., Oncogene, 8(11), 3175-3181 (1993)				
	NS	TURNER et al., Proceedings of the National Academy of Sciences of the United States				
		of America, 90(12), 5544-5548 (1993)				
	NT	UHLMANN et al., Chemical Reviews, 90(4), 543-584 (1990)				
	ΝU	VAN DEN BERG et al., Bio/Technology, 8(2), 135139 (1990)				
	NV	VERHOEYER et al., Science, 239(4847), 1534-1536 (1988)				
	NW	VILE et al., Cancer Research., 53(5), 962-967 (1993)				
	NX	VILE et al., Cancer Research, 53(17), 3860-3864 (1993)				
	NY					
	ΝZ	VLAK et al., The Journal of General Virology, 69(4) 765-776 (1988)				
	OA	WANG et al., <i>Cell, 87(4),</i> 629-638 (1996)				
	ОВ	WARNE et al., <i>Nature</i> , 364(6435), 352-355 (1993)				
<del></del>	OC	WELLING et al., FEBS Letters, 188(2), 215-218 (1985)				
		WINITZ et al., <i>The Journal of Biological Chemistry</i> , 268(26), 19196-19199 (1993)				
	OD	WOFFENDIN, Proceedings of the National Academy of Sciences of the United States of				
	OE	America, 91(24), 11581-11585 (1994)	1			
<b></b>	OF	WOTTEN et al., <i>The Journal of Biological Chemistry</i> , 268(24), 17975-17982 (1993)				
		WU, The Journal of Biological Chemistry, 264(29), 16985-16987 (1989)				
	OG	YELTON et al., Proceedings of the National Academy of Sciences of the United States				
	ОН	of America, 81(5), 1470-1474 (1984)				
	01					
<b>.</b>	0	ZABNER et al., <i>Cell, 75(2), 207-216 (1993)</i>				
	ΟJ	ZHANG et al., <i>Nature</i> , <i>364(6435)</i> , 308-313 (1993)				
*						
	<u> </u>					
	<u> </u>					
	<del>                                     </del>					
	<del>                                     </del>					
	-		<del> </del>			
	<del>                                     </del>		<b> </b>			
	ļ		<b></b>			
<u> </u>						
·			<b></b>			
			ļ			
	<u> </u>					
			<u></u>			

Examiner Signature	Date Considered	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).